Impaired S-Phase Arrest in Acute Myeloid Leukemia Cells with a FLT3 Internal Tandem Duplication Treated with Clofarabine

Claire Seedhouse,1 Martin Grundy,1,2 Shili Shang,1 John Ronan,2 Heather Pimblett,1 Nigel Russell,1,2 and Monica Pallis2

Abstract

Purpose: Acute myeloid leukemia cells with an internal tandem duplication mutation of FLT3 (FLT3-ITD) have effective DNA repair mechanisms on exposure to drugs. Despite this, the phenotype is not associated with primary resistant disease. We show defects in the response of mutant FLT3 AML cells to the S-phase drug clofarabine that could account for the apparent contradiction.

Experimental Design: We studied responses of AML cells to clofarabine in vitro.

Results: When treated with a short pulse of clofarabine, FLT3-ITD–harboring MOLM-13 and MV4.11 cells undergo similar damage levels (γH2AX foci) to wild-type cells but have a better repair capability than wild-type cells. However, whereas the wild-type cells undergo rapid S-phase arrest, the S-phase checkpoint fails in mutant cells. Cell cycle arrest in response to DNA damage in S phase is effected via loss of the transcriptional regulator cdc25A. This loss is reduced or absent in clofarabine-treated FLT3 mutant cells. Furthermore, cdc25A message levels are maintained by the FLT3-ITD, such that message is reduced by 87.5% on exposure to FLT3 small interfering RNA. Primary FLT3-ITD samples from untreated patients also display impaired cell cycle arrest and show enhanced sensitivity on prolonged treatment with clofarabine compared with wild-type samples.

Conclusion: There is a reversal of phenotype in mutant FLT3 cells dependent on the length of exposure to clofarabine. Efficient DNA repair may render the cells resistant to a short pulse of the drug, but a failure of cell cycle checkpoint(s) in S phase renders the cells sensitive to prolonged exposure. (Clin Cancer Res 2009;15(23):7291–8)

FLT3 is one of the most commonly mutated genes in acute myeloid leukemia (AML). It is a member of the type III tyrosine kinase receptor family, which promotes cell growth. Mutated FLT3 can lead to constitutive activation of the receptor and of multiple downstream genes and pathways. Approximately 30% of AML patients have mutations of the FLT3 gene in their blast cells, composed of either FLT3-internal tandem duplication (FLT3-ITD) mutations (24%; ref. 1) or FLT3 activation loop mutations (7%; ref. 1). FLT3 mutations are associated with a relatively poor prognosis in AML due to an increased relapse rate (2–4).

Clofarabine is a second-generation purine nucleoside analogue with favorable pharmacologic properties (resistance to deaminase degradation and stability in gastric acid) and is in increasing clinical use for the treatment of AML (5–9). Because of the potential oral availability and its acceptable toxicity with respect to mucositis and alopecia, its use has recently been explored in older AML patients with promising results.3

Mechanisms supporting heterogeneity in sensitivity and resistance to clofarabine have been reported in the literature; particularly, a variability in the cellular accumulation of clofarabine triphosphate in circulating blasts has been recorded (6, 7). We have previously shown efficient DNA repair following anthracycline exposure in AML cells with a FLT3-ITD (10) and were thus initially interested to discover whether DNA damage and repair mechanisms are important in the response of FLT3-ITD cells to clofarabine. There is a well-characterized assay (the measurement of γH2AX) that can be used as a biomarker of the effectiveness of clofarabine at reaching its DNA target and inducing a damage response (7, 11). The use of this assay has enabled us to focus on events subsequent to clofarabine-induced DNA damage and to dissect mechanisms by which cells proceed to apoptosis or recovery subsequent to the initial damage response signals.

The damage response pathway is closely linked to cell cycle arrest mechanisms. In a well-documented but fast-evolving model of cell cycle arrest in S phase (the phase in which

---

3 A.K. Burnett et al., submitted for publication.
Clofarabine response assays

Leukemic cells were suspended in sterile Falcon tubes at $5 \times 10^7$/mL for cell lines and $8 \times 10^7$/mL for patient cells in the medium described above. After preliminary dose-finding studies, they were cultured with clofarabine at doses specified elsewhere for the assays described below. Clofarabine was a gift from Bioenvision (now part of Genzyme) and was maintained at room temperature as a 3 mmol/L stock solution in saline. In pulsing experiments, cells were cultured with clofarabine, rinsed twice at 4°C in RPMI 1640, and resuspended in fresh medium for the remainder of the culture.

Assays for apoptosis

Apoptosis in cultured cells was assessed using flow cytometric 7-amino actinomycin D (7-AAD) and forward scatter measurements (18, 19). 7-AAD (5 µg/mL) was added to each tube 15 min before the end of culture. 7-AAD fluorescence was measured using the FL3 channel of a FACSCalibur (Becton Dickinson).

γH2AX assays

Flow cytometry. Cells were incubated at $5 \times 10^5$/mL for 1 h with and without the specified doses of clofarabine followed by two rinses in ice-cold RPMI 1640. A portion of the cells was then fixed immediately to assess baseline damage, and a portion was resuspended in fresh cell culture medium and returned to the incubator to allow time for repair to take place. Cells were harvested and fixed after 2 h further incubation. γH2AX phosphorylation was measured with a kit from Upstate according to the manufacturer’s instructions. Counterstaining to estimate intracellular DNA content was with 25 µg/mL 7-AAD in PBS. For quantitative analysis, fluorescence values obtained from untreated control cells were subtracted to ensure specificity.

Immunocytochemistry. Clofarabine-treated and control cells were fixed to glass slides using the Liqui-Prep Cytology system (LGM International), fixed in 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Unconjugated monoclonal γH2AX antibody (Upstate) was applied for 1 h. Foci were visualized using the Mach 4 herosahrid peroxiside system (BioCare Medical). As the number of foci varied per cell, these were quantified using a modification of the H score system originally developed to determine estrogen receptor status in breast carcinomas (20). In each field, the number of cells staining positively was assessed and divided into groups according to the number of foci present: N (no foci), L (1–6 foci per cell), M (7–12 foci), H (≥13 foci), and C (completely damaged, individual foci not countable). A total of 100 cells per slide were assessed and the H score was calculated as follows: $N + 2L + 3M + 4H + 5C$. The H score of untreated cells was subtracted from that of treated cells.

Bromodeoxyuridine incorporation assay

Cells at $5 \times 10^3$/mL (cell lines) or $8 \times 10^3$/mL (patient samples) were cultured with clofarabine for the times specified in Results. Following two washes, 100 µmol/L bromodeoxyuridine (BrdUrd; DAKO) was incubated with the cells for 45 min at 37°C. The cells were then washed in PBS + 1% glucose, fixed and permeabilized in cold 70% ethanol, and stored at -20°C overnight or for up to 6 days. The cells were then pelleted, incubated for 30 min in 2 mL of 2 mol/L HCl at room temperature, pelleted, incubated in 2 mL of 0.1 mol/L borax (pH 8.5) for 5 min at room temperature, and washed in PBS + 1% glucose. Immunostaining was analyzed using anti-BrdUrd-IgG-DAKO. Isotype-matched control and secondary antibodies were also from DAKO. Counterstaining to estimate intracellular DNA content was with 25 µg/mL 7-AAD in PBS.

Cdc25A measurements

Cdc25A was measured using flow cytometrically using a monoclonal primary antibody from Novus (DCS120/121) or isotype control. Cells were fixed and permeabilized with leucoperox (Ab Serotec) and incubated for 60 min with 5 µL primary antibody. Rabbit anti-mouse FITC (DAKO) was used as secondary layer.

Small interfering RNA nucleofection

Small interfering RNA (Hs_FLT3_2_HP, 1423109; control siRNA, 1022076; Qiagen) was introduced into 4 × 10^6 cells in logarithmic
growth phase using nucleofection (Amaxa). Cells were nucleofected according to the manufacturer’s guidelines; solution R (Amaxa) and program X-001 were used for the MV4-11 cell line, and solution V (Amaxa) and program T-019 were used for HL-60 nucleofection.

**FLT3 mutation analysis**

FLT3-ITDs were analyzed by previously described methods (10). ITD mutations were confirmed by analysis on a 3130 Genetic Analyzer (Applied Biosystems). Samples were also analyzed for the presence of a point mutation in the tyrosine kinase domain at codon position 835 (Asp; ref. 21).

**Quantitative PCR**

RNA was prepared from cell lines using QIAamp RNA kits with DNase treatment according to the manufacturer’s instructions (Qiagen). Up to 2 µg RNA was used in a reverse transcription reaction with MMLV reverse transcriptase (Invitrogen) and random hexamers (GE Healthcare). Quantitative PCR was done on an ABI Prism 7700 (Applied Biosystems) using Excite Real-time Mastermix with SYBR Green (Biogene). Thermal cycler conditions included incubation at 95°C 10 min followed by 40 cycles of 95°C 15 s and 60°C 1 min. Following the 40 cycles, the products were heated from 60°C to 95°C over 20 min to allow melting curve analysis to be done. This allowed the specificity of the products to be determined (single melting peak) and confirmed the absence of primer-dimers.

To enable the levels of transcripts to be quantified, standard curves were generated using serial dilutions of KG1a cDNA for cdc25a and MV4.11 for FLT3. The housekeeping gene β2-microglobulin (β2M) was used to standardize the samples and the relative expression level of cdc25a was therefore calculated as the ratio between the level of cdc25a and the level of β2M. The sequences of the primers used to quantify β2M have been published previously (22); primers for cdc25a were purchased from Qiagen (QT00001078). Negative controls (no template) were included in each experiment and all reactions were run in triplicate.

**Results**

**DNA damage response in clofarabine-treated cells.** For this study, we used MV4.11 cells that are homozygous for the FLT3-ITD, MOLM-13 that has one mutant and one wild-type allele, and two FLT3 wild-type cell lines: KG1 and HL-60. All four cell lines express FLT3 message and protein, but only the

---

**Fig. 1.** γH2AX phosphorylation in leukemic cell lines. Cells were cultured for 1 h with equitoxic clofarabine (0.3 µmol/L for HL-60 and MOLM-13 and 1 µmol/L for KG1 and MV4.11). γH2AX was measured directly after treatment.

**Fig. 2.** Flow cytometric analysis γH2AX phosphorylation. γH2AX was measured directly after treatment and following 2 h additional culture in drug-free medium to allow recovery. A represents flow cytometric dot-plots. γH2AX fluorescence on the Y axis, plotted against DNA content (7-AAD) on the X axis, directly after drug treatment and following 2 h recovery time. B, as in A. Mean of two to three independent flow cytometry experiments.
MOLM-13 and MV4.11 express phosphorylated (constitutively activated) FLT3 (data not shown). We first established a time point and doses for early cell death induced by clofarabine. We initially cultured cells for 2, 4, and 6 h with up to 1 μmol/L clofarabine, a dose that corresponds to clinically achievable plasma levels in AML patients (6, 23). We noted cell death at 6 h and established a dose for each cell line that will kill 10% to 30% of cells (data not shown). All the cells used undergo extensive damage with longer incubations (data not shown), but we deliberately chose doses that induce early cell death because a high amount of cell death can obscure the pathways used by the cell to deal with toxic insults. As resistance to clofarabine has been associated with failure of cells to incorporate the drug, it was important for us to establish whether cells were damaged by exposure to clofarabine.

H2AX is a histone variant that becomes phosphorylated on serine 139 early in the response to DNA damage (24, 25). (H2AX with phosphorylated serine 139 is also known as γH2AX.) γH2AX is important in the formation of a stable repair complex at the site of DNA damage (26) and dephosphorylation of γH2AX indicates repair (25). We pulsed cells with clofarabine for 1 h before measuring damage foci by immunocytochemistry using the H score (see Materials and Methods). The H score was 131 in MV4.11 cells and 69 in MOLM-13.
compared with 117 in KG1 and 107 in HL-60, indicating damage in all four cell lines (Fig. 1). We also pulsed cells with clofarabine for 1 h and measured γH2AX after 2 h recovery in drug-free medium using flow cytometry. In FLT3 mutant MOLM-13 and MV4.11 cells, the γH2AX positivity found in cells immediately after treatment had almost completely disappeared 2 h later (Fig. 2). In contrast KG1 cells, subjected to the same procedure, only lost 12% of γH2AX fluorescence after 2 h recovery time. The HL-60 response was intermediate. These results indicate that the FLT3-ITD cell lines efficiently repair clofarabine-induced damage as assessed by the decrease of γH2AX with time.

Clofarabine-induced reduction in DNA replication. Using BrdUrd and 7-AAD, we also measured the extent to which clofarabine inhibits DNA synthesis. We found that clofarabine reduced the proportion of cells synthesizing DNA by 91% after 1 h in KG1 cells and 80% in HL-60 but by only 1% in MOLM-13 and 9% in MV4.11 cells (Fig. 3A and B). After 1 h treatment, numerous BrdUrd-negative S-phase cells can be observed on the FACS plots of HL-60 and KG1, but not MOLM-13 or MV4.11 cells, indicating cell cycle arrest in S phase in the former but not the latter. Figure 3C shows that the continued presence of clofarabine over 3 h gradually reduces the proportion of BrdUrd-positive cells in the FLT3 mutant cell lines. This suggests that, over a prolonged period, these cells continue to synthesize DNA and therefore remain vulnerable to clofarabine incorporation. It seemed likely that, despite efficient repair processes, clofarabine-induced damage would eventually become overwhelming. We therefore monitored the proportion of γH2AX-positive MV4.11 cells over time in the continued presence of clofarabine. After a nadir at 2 h continuous culture, the proportion of γH2AX-positive cells starts to increase from 11% of total cells at 2 h to 44.5% at 6 h (Fig. 3D).

FLT3-cdc25A pathway in DNA synthesis. Aberrant activity of the cell cycle phosphatase cdc25A driven by mutant FLT3 could account for the defect in S-phase arrest in the ITD cells. Phosphorylation of cdc25A regulatory sites following DNA damage accelerates the proteolysis of cdc25A; thus, we would expect drugs that induce cell cycle arrest in S phase to induce a decrease in protein. We documented a clofarabine-induced decrease in cdc25A in the FLT3 wild-type cell lines following a 1 h exposure to clofarabine (Fig. 4A). This decrease was >50% weaker in MOLM-13 cells and not observed in MV.11 cells. Moreover, we found that siRNA to FLT3 decreases cdc25A transcript expression in MV4.11 cells by 87.5% (Fig. 4B), suggesting that the protein levels might be sustained, at least in part, by aberrant transcription. These data combine to suggest aberrant expression of cdc25A in FLT3-ITD cells sufficient to support the continued cycling of damaged cells.

Primary cells with a FLT3-ITD are sensitive to clofarabine in continuous culture compared with wild-type samples. Finally, we asked whether the defect in cell cycle arrest in damaged MOLM-13 and MV4.11 cells would also be noted in samples from patients presenting with AML. We cultured 12 primary AML samples with clofarabine for 24 h (preliminary studies having shown no response at 6 h). Two samples were excluded from analysis because of high background apoptosis in untreated cells. Both of these samples had FLT3-ITDs, which was unsurprising because we have shown previously that this phenotype has heightened susceptibility to in vitro apoptosis (27). Three of 10 remaining samples had FLT3-ITDs and one had a point mutation. The rate of proliferation in untreated cells was a major determinant of sensitivity to clofarabine (P = 0.02). Furthermore, in a subset of samples, we established, using γH2AX, that clofarabine induces DNA damage (Fig. 5A).
After 2 h clofarabine treatment, the percentage of γH2AX-positive cells was, in each case, only slightly less than the percentage of cycling cells at 1 h; that is, most, if not all, cycling cells accumulate clofarabine-induced damage. The concentration of clofarabine was not a limiting response determinant: there was no increased sensitivity to clofarabine when the dose was increased from 0.3 to 1 μmol/L (mean % cell death, 11.7% at 0.3 μmol/L and 9.8% at 1 μmol/L). These data combine to indicate that, at 0.3 μmol/L, clofarabine metabolites are able to saturate their targets in S-phase cells and induce DNA damage, but cells not in S phase are unaffected, even when the clofarabine concentration is increased. However, we also noted that the three FLT3 mutant samples with at least 5% BrdUrd positivity in untreated cells appeared particularly sensitive to clofarabine in this culture system (Table 1). To determine whether the impaired cell cycle arrest in S phase observed in MOLM-13 and MV4.11 cells would also apply to patient cells harboring FLT3 mutations, we selected the six samples in which there was at least 5% BrdUrd positivity in untreated cells and measured BrdUrd inhibition by clofarabine after 1 h treatment. In the two FLT3-ITD samples, 21.9% and 49% BrdUrd inhibition was recorded; there was 24.3% inhibition in the sample with a point mutation (Fig. 5B), whereas, in the wild-type samples, BrdUrd was inhibited by 60.3%, 77.5%, and 90.5%. The difference in BrdUrd inhibition between the three wild-type and the three mutant samples was statistically significant (P = 0.05). The rapid S-phase inhibition found in primary FLT3 wild-type cells could account for their protection from clofarabine in prolonged culture in contrast to the impaired S-phase inhibition in the sensitive FLT3 mutant cells.

<table>
<thead>
<tr>
<th>Trial no.</th>
<th>Sample</th>
<th>% Blasts*</th>
<th>% Loss of viable cells (0.3 μmol/L clofarabine)</th>
<th>% BrdUrd-positive cells before treatment</th>
<th>FLT3 status</th>
</tr>
</thead>
<tbody>
<tr>
<td>9452</td>
<td>Bone marrow</td>
<td>91</td>
<td>46</td>
<td>22</td>
<td>ITD</td>
</tr>
<tr>
<td>9437</td>
<td>Peripheral blood</td>
<td>92</td>
<td>7</td>
<td>2</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9436</td>
<td>Peripheral blood</td>
<td>84</td>
<td>0</td>
<td>7</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9444</td>
<td>Peripheral blood</td>
<td>82</td>
<td>18</td>
<td>11</td>
<td>D835Y</td>
</tr>
<tr>
<td>9425</td>
<td>Peripheral blood</td>
<td>86</td>
<td>9</td>
<td>21</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9416</td>
<td>Bone marrow</td>
<td>64</td>
<td>8</td>
<td>23</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9397</td>
<td>Peripheral blood</td>
<td>82</td>
<td>25</td>
<td>21</td>
<td>ITD</td>
</tr>
<tr>
<td>9373</td>
<td>Peripheral blood</td>
<td>82</td>
<td>0</td>
<td>1</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9356</td>
<td>Peripheral blood</td>
<td>87</td>
<td>4</td>
<td>2</td>
<td>Wild-type</td>
</tr>
<tr>
<td>9315</td>
<td>Peripheral blood</td>
<td>85</td>
<td>0</td>
<td>4</td>
<td>ITD</td>
</tr>
</tbody>
</table>

*The percentage of blasts was ascertained flow cytometrically as CD45 intermediate/side-scatter low cells.
Impaired S-Phase Arrest in AML FLT3-ITD Cells

Discussion

We have shown previously that AML cells with FLT3-ITDs mount an effective repair response on treatment with daunorubcin (10). Despite this, the poor risk FLT3-ITD phenotype is associated with an enhanced relapse risk rather than impaired remission rate (3, 4) and there is no evidence that the phenotype contributes to primary chemoresistance in randomized trial patients. The initial focus of this study was to analyze heterogeneity in the DNA damage response to clofarabine in AML, and we used the γH2AX reporter assay to show that clofarabine induces DNA damage and that FLT3 mutant cells are particularly efficient at repairing the damage following a short exposure. However, sensitivity to S-phase drugs is likely to depend, at least in part, on the cycle status of the cell, and we therefore started measuring BrdUrd and uncovered the marked difference between ITD and wild-type cells in their ability to arrest in S phase following clofarabine treatment.

We found that downregulation of FLT3-ITD by siRNA reduced cdc25A message ~10-fold in the mutated MV4.11 cell line. Cdc25A is a key regulator of cell cycle progression. Cdc25A inactivation through Chk1 mediates rapid cell cycle arrest that is independent of p53 and does not require protein synthesis (28). MV4.11 cells express wild-type p53, and a p53-dependent pathway of cell cycle arrest in S phase has recently been described, mediated by p21 and subsequent downregulation of cdc25A at the transcriptional level (29). However, we did not find that clofarabine downregulated cdc25A message in MV4.11 cells (data not shown). It is interesting that cdc25A is the key effector molecule on which the different S-phase pathways converge. In this context, the cdc25A-null phenotype is embryonically lethal and the (+/-) embryonic fibroblast shows reduced ability to undergo oncogenic transformation (30, 31).

We were motivated to investigate cdc25A because its expression is driven by c-myc (32), which is known to be aberrantly upregulated in FLT3-ITD cells (33). However, this might not be the relevant pathway: it is also of note that Pim-1, another major transcriptional target of FLT3-ITDs (34), is reported to activate cdc25A (35), although the mechanism is unclear (36). Recently, a phosphoinositide 3-kinase inhibitor has been used to downregulate cdc25A expression in Ba/F3 cells expressing a FLT3-ITD (37). Thus, there may be more than one pathway by which FLT3-ITDs upregulate cdc25A expression.

We have shown that the sensitivity of FLT3 mutant cells to clofarabine in continuous application of drug follows on from the failure to inhibit DNA synthesis, which thus prolongs the time over which drug can be incorporated into DNA. Data from primary cells studied in vitro backed up this finding, but now the exact kinetics of abnormal proliferation in the face of DNA-damaging agents needs to be worked out in cells taken from patients undergoing treatment, as knowledge of these kinetics might be used for therapeutic advantage in terms of length of infusion or timing combinations of drugs that are thought to be synergistic: there is a lot of interest in clinically effective combinations involving clofarabine, and a trial of clofarabine with cytarabine has recently been reported (9).

Finally, there is no reason to assume that mutant FLT3 is unique in activating cdc25A in leukemia cells or that clofarabine has unique effects. Findings analogous to our own have been found in other systems; for example, cdc25A depletion after cytarabine treatment was found to be dependent on another component of the pathway (rad9), such that rad9+ mouse embryonic stem cells show increased sensitivity to cytarabine (38). While this article was being prepared, an article was published indicating that NPM/ALK and BCR/ABL as well as FLT3-ITD are associated with constitutive expression of cdc25A (39). Our study thus may provide a paradigm for exploring the effect of other activating mutations on the S-phase checkpoint response to a range of S-phase drugs.

Disclosure of Potential Conflicts of Interest

M. Pallis received a grant from Bioenvision for research on clofarabine. The other authors disclosed no potential conflicts of interest.

Acknowledgments

We thank Bioenvision for a financial contribution toward reagent costs and the UK AML Adult Working Party for permission to use trial samples.

References


Impaired S-Phase Arrest in Acute Myeloid Leukemia Cells with a FLT3 Internal Tandem Duplication Treated with Clofarabine

Claire Seedhouse, Martin Grundy, Shili Shang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-1222

Cited articles
This article cites 38 articles, 23 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/23/7291.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.